| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2013 ( Subtotal = $800,000 ) |
| | 2013 | 2013 | ALEXION PHARMACEUTICALS, INC | 352 KNOTTER DRIVE | CHESHIRE | CT | 06410-1138 | CAPITOL | USA | R01FD003745 | Phase 2 Study of ENB-0040 for the Treatment of Hypophosphatasia | 002 | 3 | FDA | 7/8/2013 | $400,000 |
| | 2013 | 2013 | ALEXION PHARMACEUTICALS, INC | 352 KNOTTER DRIVE | CHESHIRE | CT | 06410-1138 | CAPITOL | USA | R01FD003745 | Phase 2 Study of ENB-0040 for the Treatment of Hypophosphatasia | 001 | 2 | FDA | 3/21/2013 | $400,000 |
|
| Issue Date FY: 2006 ( Subtotal = $1,489,683 ) |
| | 2006 | 2006 | ALEXION PHARMACEUTICALS, INC | 352 KNOTTER DRIVE | CHESHIRE | CT | 06410 | CAPITOL | USA | R43AI066611 | NEBULIZING ECULIZUMAB FOR INTRAPULMONARY C5 INHIBITION | 000 | 2 | NIH | 8/31/2006 | $295,000 |
| | 2006 | 2006 | ALEXION PHARMACEUTICALS, INC | 352 KNOTTER DRIVE | CHESHIRE | CT | 06410 | CAPITOL | USA | U01AI061311 | HUMAN ANTIBODY THERAPEUTICS AGAINST ANTHRAX | 000 | 3 | NIH | 8/11/2006 | $1,194,683 |
|
| Issue Date FY: 2005 ( Subtotal = $297,000 ) |
| | 2005 | 2005 | ALEXION PHARMACEUTICALS, INC | 352 KNOTTER DRIVE | CHESHIRE | CT | 06410 | CAPITOL | USA | R43AI066611 | NEBULIZING ECULIZUMAB FOR INTRAPULMONARY C5 INHIBITION | 000 | 1 | NIH | 8/19/2005 | $297,000 |
|
| Issue Date FY: 2004 ( Subtotal = $737,620 ) |
| | 2004 | 2004 | ALEXION PHARMACEUTICALS, INC | 352 KNOTTER DRIVE | CHESHIRE | CT | 06410 | CAPITOL | USA | U01AI061311 | HUMAN ANTIBODY THERAPEUTICS AGAINST ANTHRAX | 000 | 1 | NIH | 7/6/2004 | $737,620 |
|
| Issue Date FY: 2000 ( Subtotal = $100,000 ) |
| | 2000 | 2000 | ALEXION PHARMACEUTICALS, INC | 352 KNOTTER DRIVE | CHESHIRE | CT | 06410-1138 | CAPITOL | CHE | R43DK057963 | PREVENTION OF TYPE I DIABETES BY FUSION PROTEINS | 000 | 1 | NIH | 6/16/2000 | $100,000 |
|
| Issue Date FY: 1997 ( Subtotal = $93,760 ) |
| | 1997 | | ALEXION PHARMACEUTICALS, INC | 352 KNOTTER DRIVE | CHESHIRE | CT | 06410-1138 | CAPITOL | CHE | R43HL57733 | COMPLEMENT ACTIVATION AND MYOCARDIAL INFARCTION | 000 | 01 | NIH | 12/23/1996 | $93,760 |
|
| Issue Date FY: 1996 ( Subtotal = $265,025 ) |
| | 1996 | | ALEXION PHARMACEUTICALS, INC | 352 KNOTTER DRIVE | CHESHIRE | CT | 06410-1138 | CAPITOL | CHE | R44HL52365 | COMPLEMENT ACTIVATION AND CARDIOPULMONARY BYPASS | 000 | 03 | NIH | 9/13/1996 | $265,025 |
|
| Issue Date FY: 1995 ( Subtotal = $569,791 ) |
| | 1995 | | ALEXION PHARMACEUTICALS, INC | 352 KNOTTER DRIVE | CHESHIRE | CT | 06410-1138 | CAPITOL | CHE | R43HL52365 | COMPLEMENT ACTIVATION AND CARDIOPULMONARY BYPASS | 000 | 02 | NIH | 9/21/1995 | $469,791 |
| | 1995 | | ALEXION PHARMACEUTICALS, INC | 352 KNOTTER DRIVE | CHESHIRE | CT | 06410-1138 | CAPITOL | CHE | R43AI38644 | GENERATION OF COMPLEMENT RESISTANT RETROVIRAL VECTORS | 000 | 01 | NIH | 7/26/1995 | $100,000 |
|
|
